UPL Limited shares dropped 7% on Tuesday after reporting Q1 results. While the company returned to a profit of ₹10 crore, volume growth moderated, weighing on investor sentiment. The firm continues to navigate challenges in the agrochemicals sector while aiming to reduce its net debt.
UPL Limited saw its stock price decline by approximately 7% on Tuesday, August 4, following the release of its financial results for the first quarter of the 2026-27 fiscal year. The company reported revenue of ₹10,181 crore, representing a 10.5% increase compared to the same period last year. While the top line grew, the company noted that this was largely due to price adjustments and currency factors rather than higher sales volumes, which actually saw a 3% decline.
Financial Recovery and Margin Trends
The company reported a profit of ₹10 crore for the quarter, a recovery from the ₹88 crore loss recorded in the corresponding period of the previous year. Operating profit, or EBITDA, reached ₹1,610 crore, marking a 23% increase year-on-year. This improvement in operating profit led to an EBITDA margin of 15.8%, up 160 basis points. The management attributed these gains to a focus on more profitable product segments and better pricing discipline. Despite these improvements, the stock market reaction suggests investors are cautious, especially given the company's performance over the past year, with the share price declining 17% in that period.
Debt Management and Future Outlook
A critical monitorable for investors remains the company's balance sheet. The management has reaffirmed a long-term goal of bringing its net debt-to-EBITDA ratio below 1.5x. Achieving this will depend on the company's ability to maintain cash flow while managing its capital spending. For the remainder of the 2027 fiscal year, the company has provided guidance of 7% to 11% revenue growth, with management expecting volume-led growth to become the main driver in the coming quarters.
Divergent Views on Growth Drivers
Market analysts have expressed mixed views following the results. Brokerage firm Motilal Oswal maintained a neutral stance, noting that while the company is showing better pricing discipline and cost management, earnings estimates for the next two fiscal years remain unchanged. On the other hand, Elara Capital upgraded the stock, citing the company's resilient product pipeline in seeds and crop protection as a key strength, despite slightly reducing their EBITDA estimates for the year. Investors should continue to track whether the company can successfully shift from price-led growth to volume-led growth, as this remains essential for long-term margin stability in the competitive agrochemicals sector.